Verona Pharma PLC
NASDAQ:VRNA

Watchlist Manager
Verona Pharma PLC Logo
Verona Pharma PLC
NASDAQ:VRNA
Watchlist
Price: 53.73 USD -7.51%
Market Cap: 4.6B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one VRNA stock under the Base Case scenario is hidden USD. Compared to the current market price of 53.73 USD, Verona Pharma PLC is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VRNA Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

108
P/S
P/S
Price to Sales
108
vs History
26
vs Industry
2
Median 3Y
93.4
Median 5Y
8.9
Industry
2.4
Forward
15.1
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-22.7
Median 5Y
-12.8
Industry
20.8
Forward
199.6
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-30.8
Median 5Y
-24.5
Industry
15.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-40.3
Median 5Y
-32
Industry
22.8
More Details
22.3
P/B
P/B
Price to Book Value
22.3
vs History
7
vs Industry
1
Median 3Y
6.4
Median 5Y
6
Industry
2
More Details
104.7
EV/S
EV/S
Enterprise Value to Sales
104.7
vs History
26
vs Industry
2
Median 3Y
86.8
Median 5Y
5.3
Industry
2.5
Forward
14.2
More Details
111.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
111.5
vs History
12
vs Industry
2
Median 3Y
0
Median 5Y
0
Industry
4.9
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-17.9
Median 5Y
-10.1
Industry
12.7
Forward
41.3
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-17.8
Median 5Y
-10.1
Industry
15.8
Forward
107.3
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-26.4
Median 5Y
-20.5
Industry
14
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-26.4
Median 5Y
-20.5
Industry
18.3
More Details
70
EV/IC
EV/IC
Enterprise Value to IC
70
vs History
6
vs Industry
1
Median 3Y
44.6
Median 5Y
28.8
Industry
1.7
More Details

Multiples Across Competitors

VRNA Competitors Multiples
Verona Pharma PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Verona Pharma PLC
NASDAQ:VRNA
4.7B USD 108 -26.3 -28.8 -28.6
US
Eli Lilly and Co
NYSE:LLY
704.7B USD 15.7 66.9 38.8 42.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
381.8B USD 4.3 27.1 12.7 16.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.6 18.9 12.5 14.2
CH
Roche Holding AG
SIX:ROG
210.4B CHF 3.6 18.2 10.3 12.2
UK
AstraZeneca PLC
LSE:AZN
168B GBP 4.1 31.3 126.4 193.1
CH
Novartis AG
SIX:NOVN
186.2B CHF 4.2 18.1 11 14.1
US
Merck & Co Inc
NYSE:MRK
212.5B USD 3.3 12.4 8.4 10
IE
Endo International PLC
LSE:0Y5F
162.4B USD 70 -55.5 259.5 650.8
US
Pfizer Inc
NYSE:PFE
131.9B USD 2.1 16.5 8 11.5
P/E Multiple
Earnings Growth PEG
UK
Verona Pharma PLC
NASDAQ:VRNA
Average P/E: 26.2
Negative Multiple: -26.3 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
66.9
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
27.1
26%
1
DK
Novo Nordisk A/S
CSE:NOVO B
18.9
19%
1
CH
Roche Holding AG
SIX:ROG
18.2
16%
1.1
UK
AstraZeneca PLC
LSE:AZN
31.3
36%
0.9
CH
Novartis AG
SIX:NOVN
18.1
16%
1.1
US
Merck & Co Inc
NYSE:MRK
12.4
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -55.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.5
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
Verona Pharma PLC
NASDAQ:VRNA
Average EV/EBITDA: 433.4
Negative Multiple: -28.8 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.8
30%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.7
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
12.5
15%
0.8
CH
Roche Holding AG
SIX:ROG
10.3
8%
1.3
UK
AstraZeneca PLC
LSE:AZN
126.4
9%
14
CH
Novartis AG
SIX:NOVN
11
5%
2.2
US
Merck & Co Inc
NYSE:MRK
8.4
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
259.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
8
3%
2.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
Verona Pharma PLC
NASDAQ:VRNA
Average EV/EBIT: 1 866.8
Negative Multiple: -28.6 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.8
33%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.7
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
14.2
16%
0.9
CH
Roche Holding AG
SIX:ROG
12.2
9%
1.4
UK
AstraZeneca PLC
LSE:AZN
193.1
21%
9.2
CH
Novartis AG
SIX:NOVN
14.1
8%
1.8
US
Merck & Co Inc
NYSE:MRK
10
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
650.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
11.5
10%
1.1

See Also

Summary
VRNA intrinsic value, competitors valuation, and company profile.
DCF Valuation
VRNA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VRNA stock valuation using valuation multiples.
Wall Street Estimates
VRNA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VRNA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 243,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.